



Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

February 16, 2023

WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in Citi's 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 9:00 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Xilio Therapeutics website at <https://ir.xiliotx.com/>. A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting www.xiliotx.com and follow us on Twitter ([@xiliotx](https://twitter.com/xiliotx)) and LinkedIn ([Xilio Therapeutics, Inc.](https://www.linkedin.com/company/xilio-therapeutics)).

This press release contains hyperlinks to information that are not deemed to be incorporated by reference in this press release.

For Investor Inquiries:

Melissa Forst
Argot Partners
xilio@argotpartners.com

For Media Inquiries:

Julissa Viana
Vice President, Corporate Communications
media@xiliotx.com